Home / Business and Economy / TUDRIQEV Launches, Oncology Centers Show Early Traction
TUDRIQEV Launches, Oncology Centers Show Early Traction
29 Oct
Summary
- TUDRIQEV, a new cancer therapy, launched with a $450,000 price tag.
- Over 70% of initial target accounts engaged within weeks of launch.
- Approximately 20 institutions added TUDRIQEV to formularies rapidly.
Replimune Group, Inc. has announced the commercial availability of TUDRIQEV, a new therapy for advanced melanoma, priced at $450,000 per course. The company reported strong early engagement, with over 70% of its initial 200 target oncology institutions actively participating in workflow establishment.
Within the first three weeks of its October 6, 2026, launch, approximately 20 institutions have already added TUDRIQEV to their formularies. Financial results for the fiscal second quarter ended September 30, 2026, indicated a net loss of $57.1 million, a decrease from the previous year, alongside strategic investments in building the commercial organization.
Management anticipates broader adoption following the establishment of a permanent J-code by April 2027. Payer policies are reportedly in place with major national and regional providers, covering TUDRIQEV in line with its approved label, facilitating patient access.
